Hewitt-Pelisse Syndrome (Vulvovaginal-Gingival Lichen Planus)
Start treatment immediately with ultrapotent topical corticosteroids (clobetasol propionate 0.05% ointment) applied to all affected sites—vulvar, vaginal, and oral—as first-line therapy, with systemic corticosteroids or immunosuppressants reserved for refractory cases.
Initial Treatment Approach
The cornerstone of management is topical ultrapotent corticosteroids, which have demonstrated the highest efficacy in erosive vulvovaginal lichen planus. For vulvar lesions, apply clobetasol propionate 0.05% ointment once daily for one month, then alternate days for one month, then twice weekly for maintenance 1, 2. This regimen achieved symptom relief in 71% of patients with erosive vulvovaginal lichen planus 2.
For vaginal involvement, intravaginal corticosteroid suppositories showed 55.7% complete resolution rates (54 of 97 patients) 3. For gingival lesions, apply the same ultrapotent topical corticosteroid to oral mucosa, though absorption and tolerability differ from genital sites.
Critical caveat: Topical corticosteroids alone have an 84% recurrence rate, indicating most patients will require long-term maintenance or escalation to systemic therapy 3.
When First-Line Therapy Fails
If symptoms persist after 2-3 months of compliant topical therapy, escalate systematically:
Second-Line Options
Systemic corticosteroids: Demonstrated 88.9% complete resolution (24 of 27 patients) in the most recent systematic review 3. This represents the highest efficacy among established therapies for multi-site disease.
Triple-component therapy: Combining systemic corticosteroids + topical calcineurin inhibitors + antimetabolites (methotrexate or mycophenolate mofetil) achieved 41.6% complete resolution and is the most commonly used approach for resistant cases (66.8% of triple-therapy patients) 3.
Emerging Therapies with Promising Data
The 2026 systematic review identified newer agents with impressive efficacy:
- Tildrakizumab (IL-23 inhibitor): 88.0% complete resolution (22 of 25 patients) with only 3.2% recurrence rate 3
- Tofacitinib (JAK inhibitor): 75.0% complete resolution (6 of 8 patients) 3
These biologics and JAK inhibitors show superior recurrence profiles compared to traditional therapies, though data remain limited to small cohorts.
Real-World Sequential Approach
One case series demonstrated the practical escalation pathway: hydroxychloroquine → mycophenolate → cyclosporine, with cyclosporine ultimately achieving sustained response when combined with topical betamethasone taper 4. This reflects the reality that multiple systemic agents may need trial before finding effective therapy.
Management Pitfalls to Avoid
Do not perform surgical interventions when mucosa is actively eroded—this will worsen scarring and trigger Koebnerization 5. Surgery is only appropriate after complete disease control is achieved.
Do not rely on biopsy for diagnosis—clinical diagnosis is sufficient and pathology is often nonspecific 1. Biopsy under general anesthesia may be needed only to exclude malignancy in treatment-resistant cases 4.
Monitor for squamous cell carcinoma development—3% of patients with erosive vulvovaginal lichen planus developed malignancy in long-term follow-up 2. Regular surveillance is mandatory.
Practical Treatment Algorithm
- Months 1-3: Ultrapotent topical corticosteroids to all sites (vulvar, vaginal suppositories, oral)
- Month 3 assessment: If <50% improvement → add systemic corticosteroids
- Month 6 assessment: If still inadequate → transition to triple therapy (systemic steroid + tacrolimus + mycophenolate/methotrexate)
- Refractory disease: Consider tildrakizumab or tofacitinib based on emerging evidence 3
Maintenance strategy: Even with complete resolution, continue low-dose topical therapy (twice weekly) indefinitely, as recurrence rates approach 84% with complete cessation 3.
The multi-site involvement pattern (vulvovaginal-gingival syndrome) may extend to include otic involvement, termed "vulvovaginal-gingival-otic syndrome" 6, requiring examination of ear canals in comprehensive assessment.